PharmaVOICE - 
February 2021
Purchase Issue
In Every Issue
Letter from the Editor
Celebrating firsts… Last month we witnessed Kamala Harris sworn in [...]
By

Taren Grom, Editor

Upfront
Ogilvy Captures Response in Historic Swearing In Ogilvy captured girls [...]
By

PharmaVOICE Staff

HealthTech
Heat Monitoring Systems Could Help COVID-19 Diagnosis Trend Watch: Wearables [...]
By

PharmaVOICE Staff

Artificial Intelligence
Google DeepMind’s Protein Folding Algorithms Solve Structures Faster Than Ever [...]
By

PharmaVOICE Staff

On The Cover

Healthcare Investment Trends
Global healthcare funding hit a new record in 2020: a total of .6 billion in equity funding was raised across more than 5,500 deals, according to CB Insights. North America, Asia, and Europe all saw a boost in funding year-over-year. There were 187 healthcare mega-rounds (0M+) in 2020 — a new record. COVID-19 continues to [...]
By

Kim Ribbink and Taren Grom, Editor

Features

SHOWCASE: Decentralized Clinical Trials: Building a Collaborative Alliance for Decentralized Trials
When COVID-19 forced clinical trials across the world to shut down due to the risk it posed to patients and an overloaded healthcare system, it brought decentralized trials to the fore. Decentralized clinical trials (DCTs) have been gaining impetus for several years, supported by mobile technologies and new innovations that have made trial activities that [...]
By

PharmaVOICE Staff

Decentralized Clinical Trials (DCTs): Five Key Questions to Ask Your Partners to Optimize Strategy
Anyone who has ever had a child with a suspicious sore throat or rash has considered the convenience of getting a diagnosis over the phone. But they know that as soon as they call the doctor’s office, they are going to have to get in the car and drive to a face-to-face appointment. Until now. [...]
By

Donna Hanson, Corporate Development Director, Advanced Clinical

Decentralized, Hybrid or Traditional: Choosing the Best Option for Your Clinical Trial
While elements of decentralized and hybrid trials existed prior to the coronavirus pandemic, the ongoing crisis accelerated the demand for an alternative to the traditional, on-site model as the pharmaceutical industry was focused on managing patient safety and ensuring data integrity for COVID-19 vaccines and ongoing studies. Yet, despite this need, many sponsors are still [...]
By

EB McLindon, Senior VP, Site, Patients & Decentralized Solutions, ICON plc

DCTs Are Our Genie in the Bottle
Global events often trigger cultural disruptions that forever change the way we work. In World War II, Rosie the Riveter inspired 19 million women to enter the workforce to cover for the men at war. Economists thought it would be a temporary fix, but when the war ended women kept working, changing our economy forever. [...]
By

Josh Rose, VP and Global Head of Decentralized Clinical Trial Solutions, IQVIA

Clinical’s Crystal Ball: How the Decentralized Model Will Transform Patient Care
It is 2022 – welcome to a new era of healthcare, where patients are No. 1. With this phrasing, you may envision a football game of healthcare with rowdy fans waving foam fingers in the air, chanting boisterous incantations of support for Team Patient. Of course, this is not a game but rather the result [...]
By

Alison Holland, Head of Decentralized Trials, Medable

A Paradigm Shift Towards Better Healthcare for All
The world and technology are racing ahead of the clinical trials industry. Digital health technologies (DHTs) continue to advance while clinical research remains slow to embrace efficient technologies and offerings that are widely being deployed in healthcare. The result is a market where a new medical product costs in excess of billion and takes [...]
By

Isaac Rodriguez-Chavez, Ph.D., MHS, MS, Senior VP, Scientific and Clinical Affairs, Global Center of Excellence for Decentralized Clinical Trials and Greg Licholai, M.D., Chief Medical Information Officer, and Kent R. Thoelke, Chief Scientific Officer, Executive VP, PRA Health Sciences

Will Decentralized Trials Finally Drive Meaningful Drug Development? Transformation?
Our industry has come a long way since the early days of clinical research. However, as time goes on clinical trials are becoming more complex, and if these complexities aren’t well managed patients bear the burden. When patients sign up to participate in a clinical study, they’re placing tremendous trust in healthcare workers, investigator sites, [...]
By

Maria Fotiu, Executive VP, Decentralized Solutions, Syneos Health

Cutting Through the Noise
COVID-19 has complicated the marketing environment, and experts suggest ways to stand out in an ever-changing climate. The effects of COVID-19 have given a good shake to an already ever-changing marketing landscape, and for pharma marketers it is more difficult than ever to cut through the resounding noise of multiple channels and messages reaching important [...]
By

Robin Robinson

SHOWCASE: Rare Disease: Tackling the Barriers to Rare Disease Treatments
Efforts to address the approximately 7,000 rare diseases worldwide have intensified as life-sciences companies increasingly turn their attention to these conditions. According to some analysts reports, orphan drugs could account for one-fifth of global prescription sales by 2024. This increase in market share is being bolstered by life-sciences companies of all sizes leaning into the [...]
By

PharmaVOICE Staff

Five Recommendations to Make Trials More Child-Centric
Increasing Engagement of the Pediatric Population. Rare disease research is an increasingly competitive sector of the clinical research landscape. While rare diseases individually affect a relatively small number of patients, as a category these diseases affect millions of people – and half of those patients are children. For sponsors who are interested in developing rare [...]
By

Robin Burges, Senior Project Manager, Advanced Clinical

Unlocking Hope for Patients with Rare Diseases
One of the most insidious characteristics of rare diseases is how isolating they can be for patients and their caregivers. Those with a rare disease don’t enjoy the social sport of comparing cholesterol numbers among friends at a dinner party. Theirs is a much lonelier path of confusing symptoms, unusual blood tests, and in many [...]
By

David Ormesher, CEO, closerlook, inc.

Impactful Rare Disease Campaigns Are Grounded in Medically Inspired Approaches
Patient-rooted strategies are essential in rare disease communication and commercialization. No matter what stage a company is at, or what therapeutic area it is serving, one thing is certain: Rare diseases present unique commercialization and communication challenges that require a deep understanding of not only the disease but also the vast impact it can have [...]
By

Ian DeMeritt, Ph.D., Medical Strategist, Laura Wilson, Strategist, Dan Schroen, Head, Photo 51, Roshawn Blunt, Managing Director, 1798, Craig Mattes, Head, Phoenix Office, Fingerpaint

Opening Doors to Clinical Trial Innovation
New opportunities are available in spite of a year not worth repeating. Although 2020 was an incredibly challenging year for conducting clinical research studies due to COVID-19, many leaders acknowledge it forced the industry to rethink processes and creatively address the barriers that have often been pain points. Know Rare fielded a survey among professionals [...]
By

Nina Wachsman, CEO and Co-Founder and Jake Wachsman, Chief Operating Officer and Co-Founder, Know Rare

Success in Rare Diseases — Connections Matter
When it comes to rare diseases, the scarcity of patients requires us to make every connection matter. In the United States, a rare disease is defined as a condition affecting fewer than 200,000 people, a definition created by the U.S. Congress in the Orphan Drug Act of 1983. Rare diseases then became known as orphan [...]
By

Amy Graham, Client Engagement Officer, Ogilvy Health

A Glimmer of Hope for Rare Disease Patients & Beyond: Gene Therapy
Considerations and Challenges in an Evolving Market Two decades ago, as gene therapy was emerging as the next great frontier in modern medicine, the field was forced to recon with tragedy: the death of Jesse Gelsinger as a direct result of a gene therapy treatment he was given. For Jesse, the novel therapy showed promise [...]
By

Pete Robinson, VP, Medical and Scientific Strategy and Head, Syneos Health Cell & Gene Therapy Consortium

Fulfilling a Great Promise
Analysts attribute the continued growth of the cell and gene therapy (CGT) market to steady investment and consolidation in cell and gene therapies, with 16 out of the 20 largest biopharma companies adding CGT products to their portfolios. In the recent past, cell and gene therapies have emerged as promising treatment options for a myriad [...]
By

Carolyn Gretton

Commanders & Chiefs: Clinical Services C-Suite
CROs and other clinical services companies have positioned themselves to be valued partners to biopharma companies. The executives of these companies are charged with not only setting the strategic direction for their organization but setting the pace for innovation to make the clinical trial process more seamless, less costly, and better matched to patients’ needs. [...]
By
FEEDBACK